Delgrange Etienne, Vasiljevic Alexandre, Wierinckx Anne, François Patrick, Jouanneau Emmanuel, Raverot Gérald, Trouillas Jacqueline
Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France
Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France Université de Lyon 169372 Lyon, FranceService d'EndocrinologieCHU Dinant-Godinne UCL Namur, Université Catholique de Louvain, 5530 Mont-sur-Meuse, Namur, BelgiumCentre de Neurosciences de LyonINSERM S1028/CNRS UMR 5292, 69372 Lyon, FranceCentre de Recherche en Cancérologie de LyonINSERM U1052/CNRS UMR 5286, 69008 Lyon, FranceService de NeurochirurgieCHU de Tours, et Université François Rabelais, Tours, FranceCentre de Pathologie EstService de NeurochirurgieFédération d'EndocrinologieGroupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France.
Eur J Endocrinol. 2015 Jun;172(6):791-801. doi: 10.1530/EJE-14-0990. Epub 2015 Mar 19.
A sex difference in the progression of prolactin (PRL) tumors has been disputed for years.
To compare tumor characteristics and postoperative clinical course between men and women, and correlate data with estrogen receptor alpha (ERα (ESR1)) expression status.
DESIGN, PATIENTS, AND METHODS: Eighty-nine patients (59 women and 30 men) operated on for a prolactinoma and followed for at least 5 years were selected. Tumors were classified into five grades according to their size, invasion, and proliferation characteristics. The ERα expression was detected by immunohistochemistry and a score (0-12) calculated as the product of the percentage of positive nuclei and the staining intensity.
We found a significant preponderance of high-grade tumors among men and a lower surgical cure rate in men (23%) than in women (71%). Patients resistant to medical treatment were mainly men (7/8), six of whom showed tumor progression despite postoperative medical treatment, which led to multiple therapies and eventually death in three. The median score for ERα expression was 1 in men (range, 0-8) and 8 in women (range, 0-12) (P<0.0001). The expression of ERα was inversely correlated with tumor size (r=-0.59; P<0.0001) and proliferative activity. All dopamine agonist-resistant tumors and all grade 2b (invasive and proliferative) tumors (from ten men and four women) were characterized by low ERα expression.
PRL tumors in men are characterized by lower ERα expression, which is related to higher tumor grades, resistance to treatment, and an overall worse prognosis.
催乳素(PRL)瘤进展中的性别差异多年来一直存在争议。
比较男性和女性的肿瘤特征及术后临床病程,并将数据与雌激素受体α(ERα,ESR1)表达状态相关联。
设计、患者和方法:选取89例接受催乳素瘤手术且随访至少5年的患者(59例女性和30例男性)。根据肿瘤大小、侵袭和增殖特征将肿瘤分为五个等级。通过免疫组织化学检测ERα表达,并计算得分(0 - 12分),得分是阳性细胞核百分比与染色强度的乘积。
我们发现男性中高级别肿瘤明显占比更高,且男性的手术治愈率(23%)低于女性(71%)。对药物治疗耐药的患者主要是男性(7/8),其中6例尽管术后接受了药物治疗仍出现肿瘤进展,这导致了多种治疗,最终3例死亡。男性ERα表达的中位数得分为1分(范围0 - 8分),女性为8分(范围0 - 12分)(P<0.0001)。ERα的表达与肿瘤大小(r = -0.59;P<0.0001)和增殖活性呈负相关。所有对多巴胺激动剂耐药的肿瘤以及所有2b级(侵袭性和增殖性)肿瘤(来自10名男性和4名女性)的特征均为ERα低表达。
男性PRL瘤的特征是ERα表达较低,这与更高的肿瘤分级、治疗耐药性及总体较差的预后相关。